QSAR of Topoisomerase I Inhibitors using Cluster based Descriptor Procedure for Camptothecin Analogs

Authors

  • Virupaksha Bastikar
  • Bastikar Alpana Gupte
  • Pratima Alpana Jadav
  • Khadke Prashant
  • Desideri Alessandro

Keywords:

3D QSAR, CPT, Hierarchical Clustering, COMFA, Topoisomerase I

Abstract

This article aimed to derive Quantitative structure-activity relationship (QSAR) model for 413 camptothecin (CPT) analogs which are potent Topoisomerase I (Topo I) inhibitors by devising a methodology to integrate the molecules, choose descriptors for entire dataset, have less outliers and increase the cross validated r2 (r2cv) and conventional r2 (q2) values with minimum Standard Error of Prediction. A hierarchical clustering based QSAR equation is modeled for CPT analogs which would help to understand the CPT and the Topo I characteristics as well as assist in developing novel analogs with better inhibitory activity. The BASE model r2cv value was found to be 0.78 and q2 value 0.82. The 3 cluster based equations gave q2 value of 0.82, 0.86 and 0.86, respectively with less number of outliers and high predictive r2 (r2pred) value. The models were compared with COMFA QSAR models and they gave better prediction results. In this novel work we have optimized the 3D QSAR methodology by executing a model which identifies all the SAR characteristics of CPT and demonstrate the predictive capacity of the model for the entire CPT family unlike in earlier study wherein QSAR models are based on only specific group substitutions.

 

 

Downloads

Published

2013-09-30

Issue

Vol. 2 No. 2 (2013)

Section

Research/Review Articles

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is notpublished already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  • I/We also agree to the authorship of the article in the following order:

Author’s name

 

1. ________________

2. ________________

3. ________________

_______________

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.